Do you want to read an article? Please log in or register.
Secukinumab improves signs and symptoms of non-radiographic axial spondyloarthritis: primary results of a randomized controlled phase III study
Spinal Disorders
Related content
Further Publications Rheumatology
Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT
Arthritis Res Ther
Braun J, Blanco R, Marzo-Ortega H, Gensler LS, van den Bosch F, Hall S, Kameda H, Poddubnyy D, van de Sande M, Wiksten AS, Porter BO, Shete A, Richards HB, Haemmerle S, Deodhar A
doi: 10.1186/s13075-021-02613-9
Spinal Disorders
A 52-Week Randomized Placebo-Controlled Trial of Certolizumab Pegol in Non-Radiographic Axial Spondyloarthritis
Arthritis Rheumatol.
Deodhar A, Gensler LS, Kay J, Maksymowych WP, Haroon N,
Landewé R, Rudwaleit M, Hall S,
Bauer L, Hoepken B, de Peyrecave N, Kilgallen B, van der Heijde D
doi: 10.1002/art.40866.
Psoriasis
The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study
J Am Acad Dermatol.
Bagel J, Duffin KC, Moore A, Ferris LK, Siu K, Steadman J, Kianifard F, Nyirady J, Lebwohl M
doi: 10.1016/j.jaad.2017.05.033.
Further Publications Rheumatology
Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis
Arthritis Rheumatol.
Deodhar A, Gensler LS, Sieper J, Clark M, Calderon C, Wang Y, Zhou Y, Leu JH, Campbell K, Sweet K, Harrison DD, Hsia EC, van der Heijde D
doi: 10.1002/art.40728.
COMMENTED
Psoriatic Arthritis
Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5
★ 3
Recommended and commented by
Dr Heino Prillwitz, Faculty Member
Rheumatology (Oxford).
van der Heijde D, Mease PJ, Landewé RBM, Rahman P, Tahir H, Singhal A, Boettcher E, Navarra S, Zhu X, Ligozio G, Readie A, Mpofu S, Pricop L
doi: 10.1093/rheumatology/kez420.
COMMENTED
Spinal Disorders
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial
Lancet.
van der Heijde D, Cheng-Chung Wei J, Dougados M, Mease P, Deodhar A, Maksymowych WP, Van den Bosch F, Sieper J, Tomita T, Landewé R, Zhao F, Krishnan E, Adams DH, Pangallo B, Carlier H; COAST-V study group
doi: 10.1016/S0140-
COMMENTED
Psoriasis
Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies
Am J Clin Dermatol.
Armstrong AW, Reich K, Foley P, Han C, Song M, Shen YK, You Y, Papp KA
doi: 10.1007/s40257-018-0396-z.
Atopic Dermatitis
Nemolizumab plus topical agents in patients with atopic dermatitis and moderate-to-severe pruritus provide improvement in pruritus and signs of atopic dermatitis for up to 68 weeks: results from two phase III, long-term studies
Br J Dermatol
Kabashima K, Matsumura T, Komazaki H, Kawashima M, Nemolizumab JP01, JP02 Study Group.
doi: 10.1111/bjd.20873
Psoriatic Arthritis
Response to Secukinumab on Synovitis using Power Doppler Ultrasound in Psoriatic Arthritis: 12-week Results from a Phase III Study, ULTIMATE
Rheumatology (Oxford)
D'Agostino MA, Schett G, López-Rdz A, Šenolt L, Fazekas K, Burgos-Vargas R, Maldonado-Cocco J, Naredo E, Carron P, Duggan AM, Goyanka P, Boers M, Gaillez C
doi: 10.1093/rheumatology/keab628